

Asarina Pharma AB announces new date for the release of Annual Report for 2023

Asarina Pharma AB (publ) ("the Company") announces today that the Board has decided to postpone the release of the Annual Report for 2023 to 28 May 2024.

The previously communicated release date was 23 May 2024. The reason for the postponement is that the final phase of the preparation of the Annual Report is taking longer than expected.

For additional information, please contact:

Jakob Dynnes Hansen, CFO, Asarina Pharma AB
Telefon: +45 5132 3698
E-post: jakob.dynnes@asarinapharma.com

The Company's Certified Adviser is Carnegie Investment Bank AB (publ).

For further information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO, Asarina Pharma AB
Tel: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com

The Company's Certified Adviser is Carnegie Investment Bank AB (publ)

About Asarina Pharma

Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSAs (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.

Attachments

[Asarina Pharma AB announces new date for the release of Annual Report for 2023](#)